Stockreport

Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension

Acceleron Pharma Inc.  (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.acceleronpharma.com/investor-relations
PDF - The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance -- The trial also achieved statistically signifi [Read more]